Monday, September 27, 2021

Tag: blood cancer

#VisualAbstract Indatuximab ravtansine in combination with immunomodulatory drugs shows objective and clinical response in patients with relapsed or refractory multiple myeloma

Kathleen Lau -
0
Read more

#VisualAbstract Pembrolizumab after CD19-directed CAR T-cell therapy appears safe and may achieve clinical responses in patients with relapsed/refractory B-cell lymphomas

Kathleen Lau -
0
Read more

#VisualAbstract Obinutuzumab-atezolizumab-lenalidomide is effective and tolerable in patients with relapsed/refractory follicular lymphoma

Kathleen Lau -
0
Read more

#VisualAbstract Brentuximab vedotin with nivolumab was well-tolerated and showed durable remissions as initial salvage therapy in relapsed/refractory classic Hodgkin’s Lymphoma

Kathleen Lau -
0
Read more

#VisualAbstract Vitamin K antagonists did not increase the risk of myelodysplastic syndrome in patients with non-valvular atrial fibrillation

Kathleen Lau -
0
Read more

#VisualAbstract Underlying multiple myeloma remains the primary cause of death across all age groups of patients and across all lines of therapy

Kathleen Lau -
0
Read more

#VisualAbstract Patients with follicular lymphoma experience a plateau in therapy initiation rates during their first decade of observation after diagnosis

Kathleen Lau -
0
Read more

#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma

Kathleen Lau -
0
Read more

#VisualAbstract Obesity and body weight was not correlated with survival outcomes in patients with relapsed/refractory large B-cell lymphoma treated with CAR T-Cell therapy

Kathleen Lau -
0
Read more

#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia

Kathleen Lau -
0
Read more
123...6Page 1 of 6
© Copyright 2 Minute Medicine, Inc. All rights reserved.